Pharma giant set research on antibiotics because it doesn’t bring in any more money

Pharma giant set research on antibiotics because it doesn’t bring in any more money

Not profitable enough – so easy you can justify why big Pharma to develop antibiotics. New substances are urgently needed, because the number of multi-resistant germs on the rise. Thousands of Deaths could be the result.

Actually, the search for new antibiotics would have to run on high tours. Because more and more germs become resistant to the already existing bacteria-Killer. However, the research on the territory of one of the most important medicines in the presence of a sleeping: Small businesses can’t afford the high expenses. The big groups in the antibiotics business promises too little Profit. Why is this so, and what it means for patients, journalists researched the NDR for the programme “Panorama”. To see the on 12. September, at 21.45 PM in the ARD.

2016 wanted to develop 100 companies with new antibiotics

Only in 2016, the International pharmaceutical Association IFPMA had forged an Alliance (“AMR Industry Alliance”) to the fight against resistance. About 100 companies, including Johnson & Johnson, Novartis, Sanofi, and AstraZeneca agreed to invest in research in this area.

The snow of yesterday – according to the pharmaceutical companies Novartis and Sanofi, and AstraZeneca, the industry now has giant Johnson & Johnson confirmed that “no further antibiotics in development” were. Also, the big companies Pfizer and Allergan are developing according to estimates from industry experts no new antibiotic agents.

On The Topic Of:

  • Deaths increased six-fold: Extremely resistant bacteria spreading in Europe
  • 700.000 Deaths due to resistant bacteria per year – 3 ways out of the antibiotics crisis

Today, pharmaceutical research companies with half the force, or not at all

Of the four remaining large pharmaceutical companies that are working on the development of new antibiotics (MSD, GlaxoSmithKline, Otsuka, and Roche’s subsidiary, Genentech) received the NDR-researchers answers to specific questions, such as the number of scientists or amount of the Investments in this area.

The NDR research shows that half of the Alliance members by 2016, and their antibiotic activities shut down or have stopped. The reason: too expensive in development and too little to be profitable.

Money is earned with cancer and chronic diseases

The development cost of several Hundred million Euro and the expenses for production, international sales and marketing cannot be earned in the eyes of the industry. Because the new substances should come to this we rarely possible, and rather than Reserve antibiotics used in order of their effect not the same again fizzles.

The pharmaceutical industry is of development funds, therefore, rather in drugs for chronic diseases or in high-tech cancer drugs that can cost per dose is many thousands of euros.

Reports, Videos, backgrounds: From Monday to Friday, provided you FOCUS Online with the most important messages from the health Department. Here you can subscribe to the Newsletter easily and free of charge.

Social responsibility versus entrepreneur-interests

Because small businesses without other lucrative medicines can not afford the expensive antibiotics-development is the withdrawal of the Pharmaceutical in the eyes of many experts, fatal and “not responsible”. That said in the “Panorama”Interview with Ursula Theuretzbacher, who works as a consultant for the development of antibiotics, among other things, for the world health organization WHO. The pharmaceutical industry may finally have a responsibility for the society.

Thomas Cueni, Director-General of the IFPMA and Chairman of the “AMR Industry Alliance”, however, emphasizes that there is no company to their owners could be responsible for, to invest in areas where the risk is very high and the research is not successful and if it is, there would be no money for it.

By 2050, more people are killed by resistant bacteria than cancer

Given the growing global resistance-the problem of the industry-refusal sounds cynical. “We see that more and more antibiotics lose their effect,” says Peter Beyer of the WHO’s “Panorama”journalists. “We don’t need more antibiotics development, so we look at some point and do not know how we, the infections are to treat.”

Already at present, some 33,000 people die each year in the EU from infections with resistant bacteria worldwide, there are hundreds of thousands. Without effective antibiotic therapy, many patients are lost to intensive care units, or babies on the neonatal unit. Who weakened and prone to infections, then dies just as before 1940, when Penicillin came as the new miracle cure for use.

WHO and the United Nations are sounding the Alarm and warn that the death numbers in the rapid, if not immediate action will be taken. Thus, due to resistant germs may die by 2050, every year tens of millions of people. That would be more than today, cancer.

New antibiotics are a source of hope in the fight against super germs

FOCUS Online/Wochit New antibiotics to awaken hope in the fight against super germs